We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Using <i>In Vitro</i> Approaches To Investigate Idiosyncratic Drug-Induced Liver Injury
Webinar

Using In Vitro Approaches To Investigate Idiosyncratic Drug-Induced Liver Injury

Using <i>In Vitro</i> Approaches To Investigate Idiosyncratic Drug-Induced Liver Injury
Webinar

Using In Vitro Approaches To Investigate Idiosyncratic Drug-Induced Liver Injury

Maureen Bunger, PhD
Maureen Bunger, PhD
Senior Product Manager, ADME Toxicology Solutions, Lonza
Merrie Mosedale, Ph.D., RAC
Merrie Mosedale, Ph.D., RAC
Assistant Professor, University of North Carolina at Chapel Hill

Idiosyncratic drug-induced liver injury (IDILI) is thought to involve an adaptive immune attack on the liver. However, there is mounting evidence that a T-cell mediated attack in IDILI requires a series of early events that begin at the hepatocyte level and include the activation of stress response pathways, release of danger signals, and stimulation of the innate immune system.

This talk will describe using a combined experimental approach of gene expression profiling, exosome analysis, and high-content imaging in 2D and 3D liver cell culture models to evaluate early IDILI events and risk factors contributing to overt liver injury observed in the clinic.

Attend this webinar, to learn about:

  • In vitro approaches to identify mechanisms of IDILI
  • Emerging systems to investigate genetic risk factors
Advertisement